fc-enhanced igg1 anti-cd123 antibody

Fc-enhanced IgG1 anti-CD123 antibody refers to a class of engineered monoclonal antibodies designed to target CD123 (the alpha chain of the interleukin-3 receptor), which is overexpressed in various hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These antibodies are typically humanized IgG1 molecules that incorporate specific amino acid substitutions in the Fc region—most commonly the S239D and I332E mutations (XmAb® technology)—to increase their binding affinity for the CD16A (FcγRIIIa) receptor on natural killer (NK) cells. This enhancement significantly potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD123-positive leukemic blasts and leukemic stem cells (LSCs). The most prominent clinical candidate in this category was talacotuzumab (JNJ-56022473, CSL362), which was investigated for AML and MDS but ultimately discontinued. In research settings, these antibodies are frequently used as benchmarks or control comparators for next-generation innate cell engagers.

Other names

fc-engineered anti-cd123 antibodyfc-optimized anti-cd123 antibody